PDS Biotechnology (NASDAQ:PDSB) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

PDS Biotechnology (NASDAQ:PDSB) released its quarterly earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02, FiscalAI reports.

Here are the key takeaways from PDS Biotechnology’s conference call:

• PDS Biotechnology amended VERSATILE-003 to use progression-free survival as an interim primary endpoint, which management believes could speed an accelerated approval path and shorten the trial’s duration.
• The company said the amended design also reduces costs by lowering the trial size from about 350 patients to 250 and changing the randomization ratio to 1:1:1.
• Management highlighted continued momentum in PDS0101, saying the therapy remains a differentiated late-stage option in HPV-16 positive head and neck cancer because it is subcutaneous and requires only five doses.
• The company reported encouraging updates from its PDS01ADC program in both colorectal and prostate cancer, including published biomarker data and early clinical results that support broader immuno-oncology potential.
• First-quarter 2026 results showed a net loss of $7.3 million versus $8.5 million a year ago, with cash of $21.7 million at quarter-end and lower operating expenses year over year.

PDS Biotechnology Trading Up 22.3%

NASDAQ PDSB traded up $0.25 on Wednesday, reaching $1.35. The stock had a trading volume of 1,145,761 shares, compared to its average volume of 773,130. The stock has a fifty day moving average price of $0.87 and a two-hundred day moving average price of $0.86. The firm has a market capitalization of $73.17 million, a price-to-earnings ratio of -1.79 and a beta of 1.51. The company has a quick ratio of 2.98, a current ratio of 2.98 and a debt-to-equity ratio of 1.27. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.92.

Institutional Trading of PDS Biotechnology

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology in the fourth quarter valued at $25,000. Marshall Wace LLP acquired a new stake in shares of PDS Biotechnology in the second quarter valued at $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at $92,000. Susquehanna International Group LLP raised its stake in shares of PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after acquiring an additional 80,937 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of PDS Biotechnology by 117.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after acquiring an additional 106,300 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on PDSB. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, PDS Biotechnology presently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.